Form 8-K Akebia Therapeutics, For: Aug 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Intel shares fall as competitor reports record results
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- SanDisk shares fall on election and chip sector pressure
- Seagate Technology shares drop amid sector selloff
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
Akebia Therapeutics (AKBA) Posts Q2 Loss of 40c/Share
August 11, 2015 4:33 PM EDTAkebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.40), $0.11 better than the analyst estimate of ($0.51).
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
... MoreAkebia Therapeutics (AKBA) Discloses $50M ATM Offering
August 11, 2015 4:28 PM EDTAkebia Therapeutics (NASDAQ: AKBA) filed a prospectus supplement with the Securities and Exchange Commission that contemplates the sale of up to $50 million of shares of the Companys common stock, $0.00001 par value per share, from time to time in at-the-market offerings pursuant to a... More



